405 related articles for article (PubMed ID: 22200172)
21. Female sexual function in women using LARC methods.
Trigo ACM; Maron CC; Pinheiro MSA; da Silva SBL; Brito MB
Gynecol Endocrinol; 2022 Jan; 38(1):68-72. PubMed ID: 34672861
[TBL] [Abstract][Full Text] [Related]
22. Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial.
Margatho D; Mota Carvalho N; Eloy L; Bahamondes L
Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):344-350. PubMed ID: 30372645
[TBL] [Abstract][Full Text] [Related]
23. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
Pakarinen P; Lähteenmäki P; Rutanen EM
Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
[TBL] [Abstract][Full Text] [Related]
24. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months.
Margatho D; Carvalho NM; Bahamondes L
Eur J Contracept Reprod Health Care; 2020 Apr; 25(2):133-140. PubMed ID: 32069126
[No Abstract] [Full Text] [Related]
25. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas.
Bahamondes MV; Hidalgo MM; Bahamondes L; Monteiro I
Contraception; 2011 Nov; 84(5):e11-6. PubMed ID: 22018132
[TBL] [Abstract][Full Text] [Related]
26. Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18-44: A retrospective claims database analysis.
Law A; Liao L; Lin J; Yaldo A; Lynen R
Contraception; 2018 Apr; ():. PubMed ID: 29684326
[TBL] [Abstract][Full Text] [Related]
27. Selection and performance of the levonorgestrel-releasing intrauterine system.
Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
[TBL] [Abstract][Full Text] [Related]
28. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E; Wildemeersch P
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):192-8. PubMed ID: 11848648
[TBL] [Abstract][Full Text] [Related]
29. Effects of progestin-only long-acting contraception on metabolic markers in obese women.
Bender NM; Segall-Gutierrez P; Najera SO; Stanczyk FZ; Montoro M; Mishell DR
Contraception; 2013 Sep; 88(3):418-25. PubMed ID: 23410714
[TBL] [Abstract][Full Text] [Related]
30. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
[TBL] [Abstract][Full Text] [Related]
31. The levonorgestrel intrauterine system in nulliparous women.
Prager S; Darney PD
Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
[TBL] [Abstract][Full Text] [Related]
32. Levonorgestrel-releasing intrauterine system: why do some women dislike it?
Daud S; Ewies AA
Gynecol Endocrinol; 2008 Dec; 24(12):686-90. PubMed ID: 19172537
[TBL] [Abstract][Full Text] [Related]
33. Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland.
Backman T; Huhtala S; Tuominen J; Luoto R; Erkkola R; Blom T; Rauramo I; Koskenvuo M
Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():23-6. PubMed ID: 11336430
[TBL] [Abstract][Full Text] [Related]
34. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.
Lukes AS; Reardon B; Arepally G
Fertil Steril; 2008 Sep; 90(3):673-7. PubMed ID: 18001734
[TBL] [Abstract][Full Text] [Related]
35. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
[TBL] [Abstract][Full Text] [Related]
36. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study.
Wildemeersch D; Schacht E; Wildemeersch P
Contraception; 2002 Aug; 66(2):93-9. PubMed ID: 12204781
[TBL] [Abstract][Full Text] [Related]
37. General practitioners' views on the use of the levonorgestrel-releasing intrauterine system in young, nulligravid women, in London, UK.
Middleton AJ; Naish J; Singer N
Eur J Contracept Reprod Health Care; 2011 Aug; 16(4):311-8. PubMed ID: 21585243
[TBL] [Abstract][Full Text] [Related]
38. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
Selim MF; Hussein AF
Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
[TBL] [Abstract][Full Text] [Related]
39. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
Bahamondes L; Brache V; Ali M; Habib N;
Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
[TBL] [Abstract][Full Text] [Related]
40. Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial.
Kakaire O; Tumwesigye NM; Byamugisha JK; Gemzell-Danielsson K
Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):220-6. PubMed ID: 26895345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
